OncoMatch/Clinical Trials/NCT06433947
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
Is NCT06433947 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including OPN-6602 and Dexamethasone for relapsed multiple myeloma.
Treatment: OPN-6602 · Dexamethasone — Phase 1b, open-label study evaluating the safety, tolerability, pharmacokinetics, preliminary antitumor activity, and pharmacodynamics of OPN-6602 monotherapy and in combination with dexamethasone in subjects with relapsed and/or refractory MM.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Prior therapy
Must have received: immunomodulatory agent
Relapsed or refractory to 3 or more different prior lines of therapy for MM that included immunomodulatory agents, proteosome inhibitors, and anti-CD38 antibody
Must have received: proteasome inhibitor
Relapsed or refractory to 3 or more different prior lines of therapy for MM that included immunomodulatory agents, proteosome inhibitors, and anti-CD38 antibody
Must have received: anti-CD38 antibody
Relapsed or refractory to 3 or more different prior lines of therapy for MM that included immunomodulatory agents, proteosome inhibitors, and anti-CD38 antibody
Cannot have received: autologous peripheral stem cell transplant
Exception: allowed if >90 days before first dose
Prior autologous peripheral stem cell transplant or prior autologous bone marrow transplantation within <90 days of the first dose of study drug
Cannot have received: autologous bone marrow transplantation
Exception: allowed if >90 days before first dose
Prior autologous peripheral stem cell transplant or prior autologous bone marrow transplantation within <90 days of the first dose of study drug
Cannot have received: allogeneic stem cell transplantation
Exception: allowed if >12 months before screening and not receiving immunosuppressive medication for active graft vs host disease
Prior allogeneic stem cell transplantation or solid organ transplantation within 12 months of screening; subjects receiving immunosuppressive medication for active graft vs host disease will be excluded.
Cannot have received: solid organ transplantation
Exception: allowed if >12 months before screening and not receiving immunosuppressive medication for active graft vs host disease
Prior allogeneic stem cell transplantation or solid organ transplantation within 12 months of screening; subjects receiving immunosuppressive medication for active graft vs host disease will be excluded.
Cannot have received: chemotherapy
Exception: allowed if >2 weeks before first dose
Prior chemotherapy, targeted anticancer or radiation therapy within 2 weeks prior to first dose of study drug
Cannot have received: targeted anticancer therapy
Exception: allowed if >2 weeks before first dose
Prior chemotherapy, targeted anticancer or radiation therapy within 2 weeks prior to first dose of study drug
Cannot have received: radiation therapy
Exception: allowed if >2 weeks before first dose
Prior chemotherapy, targeted anticancer or radiation therapy within 2 weeks prior to first dose of study drug
Cannot have received: localized radiation therapy
Exception: allowed if >2 weeks before first dose
Localized radiation therapy to disease site(s) within 2 weeks of the first dose
Lab requirements
Blood counts
Kidney function
Liver function
Cardiac function
Adequate hematologic, renal, liver, cardiac function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Banner MD Anderson · Gilbert, Arizona
- Stanford Cancer Institute · Stanford, California
- Emory Winchip Cancer Center · Atlanta, Georgia
- University of Kansas Clinical Research Center · Westwood, Kansas
- Dana Farber Cancer Institute · Boston, Massachusetts
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify